Eris Lifesciences has announced the launch of its generic Semaglutide, branded as ‘SUNDAE’, marking a significant step in expanding access to advanced diabetes therapy in India. The multi-dose vial format starts at a highly accessible price of ₹1,290 per month, aiming to reach nearly 70% of the diabetic population. The company plans further convenience with a pen-device launch in April 2026.
Eris Launches Generic Semaglutide ‘SUNDAE’
Eris Lifesciences Limited announced on 20 March 2026 the launch of its generic Semaglutide under the brand name ‘SUNDAE’ in India. This launch is intended to democratize access to advanced GLP-1 receptor agonist therapy, which is transformative for Type 2 diabetes and weight management.
The product was officially launched for the domestic market on 21 March 2026 and falls under the category of Diabetes treatment.
Accessibility and Pricing Strategy
Reinforcing its commitment to affordability, Eris is introducing SUNDAE in multi-dose vial formats at highly accessible pricing. The introductory price starts at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. Eris stated this pricing improvement brings effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population.
Furthermore, the company plans to enhance patient convenience by introducing a pen-device version in April. The monthly MRPs for the pen-device strengths are planned as follows:
- 2mg/1.5ml: INR 4,000
- 4mg/3ml: INR 4,200
- 8mg/3ml: INR 4,500
Strengthening the Diabetes Portfolio
Semaglutide, a GLP-1 receptor agonist, has shown strong outcomes in glycemic control and weight reduction, presenting a significant growth opportunity given India’s rising diabetic population. Eris emphasized that this addition further strengthens its advanced diabetes portfolio and expands its role in next-generation metabolic care.
The company noted that the launch fulfills its responsibility to make advanced therapies truly accessible and affordable to a much larger patient base, leveraging its strong presence in chronic care for rapid adoption across India.
Company Background and Performance
Established in 2007, Eris Lifesciences is one of the youngest Top 20 pharma companies in India. As per AWACS data, the company currently has an annual branded formulations revenue exceeding INR 3,000+ Cr. Eris has focused on diversification across specialties including Diabetes, Cardiovascular, and Neurology, utilizing 6 manufacturing facilities to market products across India via a network of approximately 5,000 stockists and over 5,00,000+ retail pharmacies.
The company’s revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue recorded at INR 2,894 Cr. Eris has invested approximately INR 4,000 Cr over the last 3 years to diversify across geographies and therapeutic areas.
Source: BSE
